Sphingosine 1-phosphate induces Mcl-1 upregulation and protects multiple myeloma cells against apoptosis.

[1]  H. Duan,et al.  Activation of sphingosine kinase mediates suppressive effect of interleukin‐6 on human multiple myeloma cell apoptosis , 2007, British journal of haematology.

[2]  O. Cuvillier.  Sphingosine kinase-1 – a potential therapeutic target in cancer , 2007, Anti-cancer drugs.

[3]  J. Pfeilschifter,et al.  Altering the sphingosine-1-phosphate/ceramide balance: a promising approach for tumor therapy. , 2006, Current pharmaceutical design.

[4]  R. Sabbadini,et al.  Targeting sphingosine-1-phosphate for cancer therapy , 2006, British Journal of Cancer.

[5]  N. Gray,et al.  Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate* , 2004, Journal of Biological Chemistry.

[6]  N. Gray,et al.  Sphingosine 1-Phosphate ( S 1 P ) Receptor Subtypes S 1 P 1 and S 1 P 3 , Respectively , Regulate Lymphocyte Recirculation and Heart Rate * , 2004 .

[7]  H. Nagawa,et al.  Sphingosine-1-phosphate receptor subtype-specific positive and negative regulation of Rac and haematogenous metastasis of melanoma cells. , 2003, The Biochemical journal.

[8]  N. Sugimoto,et al.  Ligand-dependent Inhibition of B16 Melanoma Cell Migration and Invasion via Endogenous S1P2 G Protein-coupled Receptor , 2003, Journal of Biological Chemistry.

[9]  N. Mochizuki,et al.  Development of novel EDG3 antagonists using a 3D database search and their structure-activity relationships. , 2002, Journal of medicinal chemistry.

[10]  S. Milstien,et al.  Sphingosine 1-Phosphate, a Key Cell Signaling Molecule* , 2002, The Journal of Biological Chemistry.

[11]  OsamuMatsui,et al.  Sphingosine-1-Phosphate, a Platelet-Derived Lysophospholipid Mediator, Negatively Regulates Cellular Rac Activity and Cell Migration in Vascular Smooth Muscle Cells , 2002 .

[12]  T. Hla,et al.  Lysophospholipids--Receptor Revelations , 2001, Science.

[13]  M. Kuo,et al.  The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway , 2001, Oncogene.

[14]  N. Sugimoto,et al.  Subtype-specific, differential activities of the EDG family receptors for sphingosine-1-phosphate, a novel lysophospholipid mediator , 2001, Molecular and Cellular Endocrinology.

[15]  Ming-Tsan Lin,et al.  The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6 , 2001, Oncogene.

[16]  S. Milstien,et al.  Functions of a new family of sphingosine-1-phosphate receptors. , 2000, Biochimica et biophysica acta.

[17]  S. An.  Molecular Identification and Characterization of G Protein‐Coupled Receptors for Lysophosphatidic Acid and Sphingosine 1‐Phosphate , 2000, Annals of the New York Academy of Sciences.

[18]  R. Bataille,et al.  IL‐6 up‐regulates Mcl‐1 in human myeloma cells through JAK / STAT rather than Ras / MAP kinase pathway , 1999, European journal of immunology.

[19]  R. Bataille,et al.  Mcl‐1 and Bcl‐xL are co‐regulated by IL‐6 in human myeloma cells , 1999, British journal of haematology.

[20]  Y. Igarashi,et al.  Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. , 1997, Journal of biochemistry.

[21]  Y. Igarashi,et al.  Sphingosine 1-Phosphate Induces Platelet Activation through an Extracellular Action and Shares a Platelet Surface Receptor with Lysophosphatidic Acid* , 1997, The Journal of Biological Chemistry.

[22]  S. Hakomori,et al.  Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets. , 1995, Blood.